The anti-neprilysin market comprises drugs that act by inhibiting neprilysin, a zinc metalloprotease enzyme responsible for degrading vasoactive peptides like natriuretic peptides and bradykinin. These drugs are prescribed for conditions like heart failure, hypertension etc. Anti-neprilysin drugs offer advantages like improved cardiac function, better renal function and reduced inflammation. The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of cardiovascular diseases around the globe is one of the major factors fueling the growth of anti-neprilysin market. According to World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. Over 75% of these deaths take place in low- and middle-income countries. The rising cases of hypertension, heart failure and other heart diseases have accelerated the demand for drugs like anti-neprilysin that can help manage these conditions more effectively.
SWOT Analysis
Strength: The anti-neprilysin market is driven by the increasing prevalence of cardiovascular diseases. It has a novel mechanism of action in the treatment of heart failure.
Weakness: The drugs in this market are associated with side effects like hypotension, angioedema and kidney issues which can limit their use. Developing novel neprilysin inhibitors with improved safety and tolerability is a challenge.
Opportunity: There is significant unmet need for safer and more effective treatment options for HF patients. Ongoing research on the role of neprilysin inhibitors in combination with other heart failure drugs can create new opportunities.
Threats: Stiff competition from established heart failure drugs poses threat to neprilysin inhibitor drugs. Shortcomings in reimbursement policies can also restrict the market growth to some extent.
Key Takeaways
The global anti-neprilysin market is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis – North America is holding the largest share in the global anti-neprilysin market. According to statistics, over 6 million Americans suffer from heart failure and it is a major cause of mortality. Hence companies are actively engaging in R&D to introduce better drugs. Europe also has significant demand for HF drugs attributed to aging population vulnerable to cardiac issues.
Key players – BIOPROJET, one of the leading players, is developing candidate BJ-657 for treating heart failure. Novartis’ Entresto which combines neprilysin inhibitor sacubitril with valsartan has emerged as a major branded drug. Pharmaleads is working on novel neprilysin inhibitors in combination with other heart failure medications. The established players are investing in clinical trials to expand the use of neprilysin inhibitors in heart failure patient segments.